SPL Medical, based at the Novio Tech Campus in Nijmegen, is starting an international registration study for its contrast agent ferrotran. The study, which aims to demonstrate the diagnostic efficacy of the agent, is being conducted in ten hospitals in Germany, Switzerland and the Netherlands, including Radboudumc.
Mini-metastases in the picture
Ferrotran is a product of the Radboudumc spin-off SPL Medical. The contrast agent makes very small metastases in the lymph nodes highly visible on MRI scans. Even mini-metastases less than two millimeters in diameter can be detected with this approach. The drug consists of nano-iron particles, which make normal lymph nodes on an MRI scan appear black, while abnormal glands appear white. This makes it very easy to distinguish them from each other. Because ferrotran also makes the lymph vessels visible, the mini-metastases can be located with outstanding accuracy. This enables treatment – for example with targeted radiotherapy – at an early stage, resulting in fewer side effects and improving the chance of a cure. Other diagnostic techniques are limited in resolution to four to six millimeters and cannot detect such small metastases.
The first version of the product was developed in the USA in the late 1990s. Jelle Barentsz, professor of Functional Imaging at Radboudumc, discovered the value of this drug in patients with lymph node metastases. "He managed to obtain the rights for the drug for Radboudumc," says Harrie van Baars, Chief Business Officer at SPL Medical. "He then continued developing the product to make very small metastases visible."
According to Barentsz, clinical studies at Radboudumc have included hundreds of patients with various forms of cancer, such as cancer of the rectum, esophagus, pancreas, head-and-neck and prostate. "The results were so encouraging," he says, "that the product was privatized in 2015 with the spin-off SPL Medical."
Although a great deal of research data on ferrotran has been published in scientific journals, the product has not yet been authorized for the market. This requires a clinical registration study, which is now beginning. Van Baars: “This study is the prelude to the official authorization and market introduction of the product in Europe. We will study the use of ferrotran in 180 patients in ten hospitals in Germany, Switzerland and the Netherlands, including Radboudumc."
Although the agent has not yet been authorized for the market, it can sometimes be used for approved clinical studies, such as those taking place at Radboudumc. Some hospitals can also use the agent under strict conditions as part of a ‘compassionate use’ program for patients with life-threatening, long-lasting or seriously debilitating illnesses. Van Baars: “In that context, the first patient with metastatic prostate cancer in Switzerland has recently received ferrotran. With the clinical trial and the compassionate use program, our goal of making ferrotran widely available for cancer patients has come much closer to realization.”
Lowlands Science call for projects17 February 2020
Researchers pay attention! Lowlands is looking for research teams to participate in Lowlands Science 2020. It’s a great way to reach a large audience, do unique experiments with and on them, and to have a memorable experience with your colleagues.Read more
Five ZonMw ‘Off Road’ grants for Radboudumc researchers17 February 2020
Benoit Besson, Annemarie Boleij, Jonne Doorduin, Jorik Nonnekes and Sara Roig Merino have each received an ZonMw ‘Off Road’ grant of €100,000. The grants are intended for biomedical health researchers who dare to go off the beaten track in their search for new insights and unexpected breakthroughs.Read more
Dutch Kidney Foundation PhD grant for Johan van der Vlag and Tom Nijenhuis14 February 2020
Johan van der Vlag and Tom Nijenhuis, theme Renal disorders, received this grant for their joint research project “Targeting a novel paracrine signaling pathway between glomerular endothelium and podocytes to treat glomerular injury”.Read more
KNAW Early Career Award for Geert Litjens13 February 2020
Twelve young researchers received the Early Career Award from KNAW on 4 february. One of them is RIHS researcher Geert Litjens. The Award is aimed at researchers in the Netherlands at the start of their career who are capable of developing innovative and original research ideas.Read more
Interactive career day for Postdocs and PhD candidates13 February 2020
45 Postdocs and PhD candidates attended the first Interactive career day organised by Janssen Pharmaceutica, to learn more about career perspectives and R&D activities that on the longer term can lead to ideas and potential future collaboration.Read more